pharma · Alopecia areata · Multiple myeloma
First Biotech (Australia)
Pfizer Australia Pty Ltd
Pfizer Australia Pty is a pharma organization headquartered in AU. Primary therapeutic focus areas include Alopecia areata, Multiple myeloma, Heart failure, Acute Migraine (with or without aura), Transthyretin amyloidosi
Norwest House, 710 Collins Street, Melbourne, VIC 3008, AU HQ
2017 Founded
2 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- Norwest House, 710 Collins Street, Melbourne, VIC 3008, AU
- Founded
- 2017
- Employees
- 2
- Programs
- 126
- Drugs
- 208
- Patents
- 0
C0371017
Phase 3 · small molecule · hemophilia A, severe to moderately severe hemophilia B (FIX:C ≤ 2%)
C0371017 for hemophilia A, severe to moderately severe hemophilia B (FIX:C ≤ 2%) is a Phase 3 program (small_molecule) at Pfizer Australia Pty Ltd with 1 ClinicalTrials.gov record(s).
Internal code C0371017
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Pfizer Australia Pty Ltd
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- hemophilia A, severe to moderately severe hemophilia B (FIX:C ≤ 2%)
- Status
- active
- Trials
- 1